HC ANDERSEN CAPITAL

Ascelia Pharma – Presentation of interim Q3 2025 report

Name: Ascelia Pharma – Presentation of interim Q3 2025 report
Start: 2025-11-06T12:00:00+0100
End: 2025-11-06T12:30:00+0100

AUTHOR

Mie

DATE

14. October 2025

Ascelia Pharma – Presentation of interim Q3 2025 report

Ascelia Pharma – Presentation of interim Q3 2025 report 06 NovemberNov 2025 12:00 - 12:30Online Event

Information

Ascelia Pharma – Presentation of interim Q3 2025 report 06 NovemberNov 2025 12:00 - 12:30

Ascelia Pharma – Presentation of interim Q3 2025 report Online Event

ExpreS2ion Biotechnologies – Presentation of Q3 2025 Earnings Release

SP Group – Presentation of the quarterly report for Q3 2025

Explore our services

INFORMATION

Bredgade 23B 2. sal
1260 København K
View on map
Phone: 28 74 66 40
CVR: 41474793

About

What we do

HC Andersen Capital was established in 2020 and is at the forefront of digital Investor Relations, amplifying market presence.

Our tailored services encompass IR and ESG advisory, Legal Support, cutting-edge digital solutions such as IR websites and IR distribution software, Commissioned Research, Corporate Finance advisory and more. We are proudly Certified Adviser on Nasdaq First North Copenhagen.

About us

What we do in short

Advisory

IR Services

Our Community

Ascelia Pharma – Presentation of interim Q3 2025 report

Ascelia Pharma – Presentation of interim Q3 2025 report

Information

Explore our services

INFORMATION

About

What we do

2024 - HC Andersen Capital